AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Smith & Nephew (SNN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

25.94

0.24 (0.93%)

At close: Feb 18, 2025, 3:59 PM

undefined% (undefined)

Bid	25.59
Market Cap	11.31B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.7
PE Ratio (ttm)	37.06
Forward PE	n/a
Analyst	Buy

Ask	26.36
Volume	732,525
Avg. Volume (20D)	775,764
Open	26.00
Previous Close	25.70
Day's Range	25.86 - 26.09
52-Week Range	23.65 - 31.72
Beta	undefined

About SNN

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint re...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Nov 16, 1999

Employees 18,000

Stock Exchange NYSE

Ticker Symbol SNN

Website https://www.smith-nephew.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for SNN stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

7 months ago

Smith & Nephew shares are trading higher after a F... Unlock content with Pro Subscription

News

2 weeks ago · seekingalpha.com

Smith & Nephew Getting No Credit For Self-Improvement Efforts

Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing pressures in China, raising concerns about its ongoing multiyear restructuring prog...

2 months ago · zacks.com

SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA

Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.

2 months ago · zacks.com

SNN Stock Might Rise Following FDA Nod for AETOS Stemless

Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.

2 months ago · proactiveinvestors.co.uk

Smith & Nephew has the potential to pop next year, says leading US investment bank

JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potenti...